The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma.

ABSTRACT: Hepatocellular carcinoma is a poor prognosis tumor. Systemic therapies are frequently used due to frequent recurrences after surgical or radiologic treatments. Anti-angiogenic tyrosine kinase inhibitors have shown efficacy in monotherapy, but with very low rates of long survival and exceptional recovery. Immuno-oncology based on immune checkpoint inhibitors has revolutionized the systemic therapies since showing long survival rates without any tumor progression or recurrence for some patients in partial or complete response, and possibly for some patients in stable disease. However, the rate of responders under immuno-oncology monotherapy is too low to increase significantly the median overall survival of the treated patients. The immuno-oncology-based combinations with different types of

SUBMITTER: Merle P 

PROVIDER: S-EPMC7826922 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature